Q4 2024 Elanco Animal Health Inc Earnings Call Transcript
Key Points
- Elanco Animal Health Inc (ELAN) reported its sixth consecutive quarter of revenue growth, with a 4% increase on an organic constant currency basis.
- The company successfully launched six potential blockbuster products, exceeding its innovation revenue target for 2024.
- Elanco Animal Health Inc (ELAN) paid down approximately 25% of its debt in 2024, supported by strong operating cash flow and the sale of its aqua business.
- The company achieved market share gains in global pet retail and US farm animal sectors, holding leadership positions in these areas.
- Elanco Animal Health Inc (ELAN) expects continued growth in 2025, with anticipated organic constant currency revenue growth of 4% to 6% and adjusted EBITDA growth of 1% to 5%.
- Elanco Animal Health Inc (ELAN) faces challenges from foreign exchange headwinds, which negatively impacted its fourth quarter results and 2025 guidance.
- The company experienced a decline in international farm animal revenue due to challenging swine economics in Asia and commercial model changes in certain geographies.
- The adoption of the canine arbovirus monoclonal antibody has been slower than expected, impacting the company's innovation contributions.
- Elanco Animal Health Inc (ELAN) anticipates a decline in gross margin due to the UK CMO transition and FX headwinds.
- The company expects increased operating expenses in 2025, driven by strategic investments in global product launches, which may impact short-term profitability.
Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health's fourth quarter 2024 earnings conference call.
(Operator Instructions) Thank you. I woulrd now like to hand the call over to Tiffany Kanaga, Head of Investor Relations. You may begin your conference.
Good morning. Thank you for joining us for Elanco Animal Health's fourth quarter 2024 earnings call. I'm Tiffany Kanaga, Vice President of Investor Relations and ESG. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer; Todd Young, our Chief Financial Officer; and Beth Haney from Investor Relations. The slides referenced during this call are available on the investor relations section of elanco.com.
Today's discussion will include forward-looking statements. These statements are based on our current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
